Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: evaluation report

01 - NICE's response to comments on the Appraisal Consultation Document (ACD)
02 - Consultee comments on the ACD – Roche Products
03 - Consultee comments on the ACD - Target Ovarian cancer
04 - Consultee comments on the ACD – Royal college of Nursing
05 - Consultee comments on the ACD – Department of Health
06 - ERG Erratum from BMJ-TAG